Ovofert Tablet contains Clomiphene 50mg, a selective estrogen receptor modulator primarily used to induce ovulation in women experiencing anovulatory infertility. Clomiphene acts by binding to estrogen receptors in the hypothalamus, thereby inhibiting negative feedback of endogenous estrogens and promoting increased secretion of gonadotropin-releasing hormone (GnRH). This, in turn, stimulates the anterior pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), facilitating follicular development and ovulation. Ovofert is indicated for the treatment of infertility associated with polycystic ovary syndrome (PCOS), unexplained anovulation, or other ovulatory disorders. The recommended dosage typically involves administration for five days early in the menstrual cycle, with monitoring of follicular response through ultrasound and hormonal assays. Common adverse effects may include hot flashes, abdominal discomfort, visual disturbances, and ovarian enlargement. Caution is advised in patients with hepatic impairment, uncontrolled thyroid or adrenal dysfunction, and those with a history of ovarian cysts or hypersensitivity to Clomiphene. Ovofert should be prescribed and monitored by a healthcare professional experienced in fertility management to optimize therapeutic outcomes and minimize risks such as ovarian hyperstimulation syndrome and multiple pregnancies.